Bortezomib Treatment to Potentiate the Anti-tumor Immunity of Ex-vivo Expanded Adoptively Infused Autologous Natural Killer Cells
Bortezomib Treatment to Potentiate the Anti-tumor Immunity of Ex-vivo Expanded Adoptively Infused Autologous Natural Killer Cells
复制标题
DOI：
10.7150/jca.2.383
复制
发表时间：
2011-01-01
影响因子：
3.9
通讯作者：
Childs, Richard W.
中科院分区：
文献类型：
--
作者：
Lundqvist, Andreas;Berg, Maria;Childs, Richard W.
我们的研究结果表明，使用EBV-LCL饲养细胞系，大量的高活化NK细胞的纯群体可以在GMP条件下离体扩增。除甲状腺炎和与IL-2治疗相关的全身症状外，输注高达1 x 10（8）个细胞/kg的离体扩增NK耐受性良好，并为晚期癌症患者介导抗肿瘤免疫提供了初步临床证据。
Our results show that using an EBV-LCL feeder cell line, large numbers of pure populations of highly activated NK cells can be expanded ex vivo under GMP conditions. With the exception of thyroiditis and constitutional symptoms related to IL-2 therapy, infusions of up to 1 x 10(8) cells/kg of ex vivo expanded NK have been well tolerated and have provided preliminary clinical evidence for mediating anti-tumor immunity in patients with advanced cancer.